New hope for stomach cancer: drug combo aims to wipe out tumors before surgery
NCT ID NCT07374250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug ivonescimab to standard chemotherapy (SOX) can better shrink or eliminate tumors in people with locally advanced stomach or gastroesophageal junction cancer before surgery. About 154 adults aged 18-75 will be randomly assigned to receive either the combination or chemotherapy alone for about 4 months. The main goal is to see if the combination leads to a complete disappearance of cancer cells in the tumor sample after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can surgery for stomach or esophageal cancer cloud the mind?
- Can an immunotherapy combo shrink stomach tumors before surgery?